News

This week, ALLG’s National Blood Cancer Registry (NBCR) contributed to a new study on acute myeloid leukaemia (AML) published in the Journal of Clinical Oncology.

This collaborative effort looked retrospectively at various international registry data to determine how the presence of a specific genetic abnormality, NPM1, relates to clinical outcomes in those with AML. The results are significant because they allow a more advanced look into a patient’s genetic risk profile and which treatments may be most effective.

Co-authors on the publication, Associate Professor Andrew Wei and Drs Ing-Soo Tiong and Meaghan Wall have been major contributors to the medical and cytogenetic curation of the data for the NBCR and are to be commended for their work, which has led to this successful international collaboration.

Australia’s NBCR was established in 2012 under the leadership of Associate Professor Wei. To learn more about the NBCR, please visit: https://www.allg.org.au/clinical-trials-research/national-blood-cancer-registry/